IMMUTEP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.455 AUD | +4.60% |
|
-1.09% | +31.88% |
| May. 17 | Capital One Initiates Immutep at Overweight Rating With $10 Price Target | MT |
| May. 15 | Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.55M 2.38M | Sales 2025 * | 14.85M 9.94M | Capitalization | 541M 362M |
|---|---|---|---|---|---|
| Net income 2024 * | -45M -30.11M | Net income 2025 * | -44M -29.44M | EV / Sales 2024 * | 131 x |
| Net cash position 2024 * | 75.11M 50.26M | Net cash position 2025 * | 61.67M 41.27M | EV / Sales 2025 * | 32.3 x |
| P/E ratio 2024 * |
-11.9
x | P/E ratio 2025 * |
-12.7
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.19% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.60% | ||
| 1 week | -1.09% | ||
| Current month | +5.81% | ||
| 1 month | +30.00% | ||
| 3 months | +33.82% | ||
| 6 months | +54.24% | ||
| Current year | +31.88% |
1 week
0.43
0.47
1 month
0.340.49
Current year
0.330.49
1 year
0.260.49
3 years
0.230.73
5 years
0.100.73
10 years
0.101.90
| Managers | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | Feb. 13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.455 | +4.60% | 1,061,511 |
| 24-05-16 | 0.435 | -2.25% | 1,404,008 |
| 24-05-15 | 0.445 | -1.11% | 1,958,038 |
| 24-05-14 | 0.45 | -1.10% | 957,345 |
| 24-05-13 | 0.455 | -1.09% | 2,760,570 |
Delayed Quote Australian S.E., May 17, 2024 at 02:10 am EDT
More quotes
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.455
AUD
Average target price
0.978
AUD
Spread / Average Target
+114.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.88% | 362M | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- IMM Stock
